Echocardiographic strain imaging with two-dimensional speckle tracking is an emerging tool for defining cardiac function and identifying preclinical hypertrophic cardiomyopathy (HCM). In HCM, a reverse septal contour is a strong predictor of mutation positive sarcomeric HCM. The objective of this study was to determine whether left ventricular (LV) deformation patterns can differentiate between genotype positive and negative patients within a large HCM cohort.
Background
Hypertrophic cardiomyopathy (HCM) is a cardiovascular genetic disorder characterized by left ventricular hypertrophy (LVH) in the absence of an identifiable hemodynamic aetiology. Genetic testing for pathogenic mutations permits identification of patients with genetic susceptibility for myofilament/sarcomeric HCM before development of LVH. Hundreds of mutations scattered among .25 HCM-susceptibility genes have been identified, most commonly involving sarcomeric (myofilament) proteins, 1 with the majority of mutations ( 80% of genotype-positive HCM) found in two genes: MYBPC3-encoded myosin binding protein C and MYH7-encoded beta myosin heavy chain. The overall yield of genetic testing is around 35 -60% depending on patient cohort. 2 Histologically, HCM is characterized by cardiomyocyte hypertrophy, myofibrillar disarray, increased loose connective tissue, and interstitial fibrosis, resulting in regional and global abnormal generation of contractile force and hindered relaxation. 3 Two-dimensional myocardial strain assessment with speckle tracking analysis is a sensitive, angle-independent, and increasingly available tool for assessment of both global and regional myocardial function. 4, 5 Strain can help distinguish physiologic hypertrophy in athletes from HCM. 6 -8 Within HCM, strain has been correlated positively with degree of LVH. 9 Global longitudinal systolic strain and strain rate significantly differ between preclinical genotype-positive subjects and patients with overt HCM 10 and there are regional differences between preclinical genotype-positive subjects and controls. 4 Furthermore, reverse septal morphology is a strong predictor of a positive genetic test with a yield .70%.
11,12
There is no data as to whether strain patterns differ in genotypepositive compared with genotype-negative patients with HCM. Given the known predilection of septal contour/morphology with genotypic positivity, we postulated that speckle tracking echocardiography could further predict genotype positivity. Specifically, we hypothesized that left ventricular (LV) deformation patterns assessed by speckle tracking echocardiography would differ based upon the underlying pathogenic substrate (i.e. genotype) in a large cohort of patients with overt HCM.
Methods

Patient selection
The study population was selected from a cohort of 1053 HCM patients who underwent comprehensive genotyping for nine myofilament HCM-associated genes for research purposes between 1999 and 2007. All patients had clinically and echocardiographically confirmed HCM evaluated at the Mayo Clinic (Rochester, MN, USA). The diagnosis of HCM was based on the presence of myocardial hypertrophy in the absence of local or systemic aetiologies. 13 -15 All patients were evaluated clinically with diagnostic evaluation to exclude HCM mimickers (amyloidosis, Fabry's disease, etc). Patients were included in the study if they underwent transthoracic echocardiography with prospective LV longitudinal strain imaging inclusive of all 17 myocardial segments between February 2009 and April 2012. Need for pacing at the time of strain analysis was considered an exclusion criterion, given potential for altered electromechanical activation and effect on strain analysis. All patients provided consent for use of their medical records for research purposes in accordance with Minnesota law and an Institutional Review Board approved study, resulting in a final study population of 131 patients.
Echocardiographic evaluation
Comprehensive two-dimensional transthoracic echocardiography was performed in all patients. Left ventricular cavity size, wall thickness, and ejection fraction were determined in standard fashion. 16 Left atrial volume index was measured from two orthogonal views using a standard methodology. 17 , where v is peak LV outflow tract velocity). Septal morphology was classified as sigmoidal, reverse curve, apical, or neutral at the time of echocardiographic evaluation. Classification was performed on the basis of two-dimensional imaging using the long-axis view at end diastole, as previously described ( Figure 1) . 1, 12 In patients with prior septal reduction therapy, the 'native' septal morphology was recorded, supplemented by prior imaging and operative reports. Prospective two-dimensional speckle tracking analysis was performed from the apical four-chamber, apical long axis, and apical two-chamber Deformation patterns in genotyped HCM views in all patients. All imaging was obtained on a GE Vivid 7 or E9 ultrasound system (GE Medical Systems, Milwaukee, WI, USA). Sector width and depth were optimized at the time of acquisition to obtain maximal frame rates. On-line image analysis was performed at the time of image acquisition to ensure adequate speckle tracking utilizing EchoPAC software (GE Medical Systems). After ensuring similar heart rates between clips, the endocardium was manually traced in end diastole, and automated speckle tracking was performed by the software throughout the cardiac cycle. Speckle tracking allows angle-independent tracking of twodimensional natural acoustic myocardial speckles. 5,10,19 -22 Myocardial tracking was confirmed visually and through EchoPAC speckle tracking quality analysis. Adjustments to the region of interest or manual correction of the tracing contour were performed, if initial tracking was of insufficient quality. Only patients with adequate image quality to prospectively determine peak longitudinal systolic strain from all 17 LV myocardial segments (six basal, six mid, and five apical segments) were included (30 patients excluded). Longitudinal strain is reported for each individual myocardial segment, the average of apical segments, the average of mid segments, the average of basal segments, and a global average of all segments.
Genetic evaluation
All patients underwent comprehensive genotyping of nine myofilament HCM-associated genes (MYBPC3, MYH7, TNNT2, TNNI3, TNNC1, TPM1, MYL2, MYL3, and ACTC1) using polymerase chain reaction (PCR), denaturing high performance liquid chromatography (DHPLC, WAVE TM , Transgenomic, Omaha, NE, USA) and direct DNA sequencing as previously described. 23 -25 In brief, each amplicon of the nine genes was amplified using PCR and subjected to heteroduplex analysis by DHPLC. Samples with an abnormal DHPLC profile were sequenced to determine the nature of the nucleotide substitution. This technique has been demonstrated to have a sensitivity of 95% detection. 26 -28 Variants were named according to standard mutation nomenclature. PCR and WAVE conditions are available upon request.
Statistical analysis
Continuous variables are expressed as mean + standard deviation. Correlations of continuous variables were examined using simple linear regression analysis. Student's t tests, Pearson x 2 analyses, and Fischer exact tests were used as appropriate. Statistical significance was set a priori at P , 0.05.
Results
Study population
The study population consisted of 131 patients (89 males, age 55 + 15 years) with clinically diagnosed HCM ( Table 1 ). Genetic testing revealed that 51 out of 131 patients (39%) were mutation-positive for sarcomeric/myofilament-HCM (genotype positive). Clinical variables between genotype positive patients and those who were mutation negative for sarcomeric/myofilament-HCM (genotype negative) were similar, although genotype-positive patients were generally diagnosed at a younger age and were more likely to have a family history of HCM. As expected, among genotype-positive patients, the majority of mutations involved myosin binding protein C (MYBPC3; n ¼ 27, 53%) and myosin heavy chain (MYH7; n ¼ 18, 35%).
Transthoracic echocardiography
Vital signs and two-dimensional transthoracic echocardiographic findings are listed in Table 2 . Mean blood pressure was 119/ 71 mmHg, while mean heart rate was 62 bpm. LV outflow tract gradient for the study population was 33 + 40 mmHg, with no significant difference between genotype-positive and genotype-negative patients.
As shown previously, genotype-positive patients were significantly more likely to have a reverse septal curvature compared with genotype-negative patients. Conversely, genotype-negative patients 
Longitudinal strain analysis
Representative longitudinal strain analysis is depicted in (Figure 2 ). Global peak systolic longitudinal strain did not significantly differ between genotype-positive and genotype-negative patients. However, regional strain was lower in genotype-positive patients in the mid inferoseptal (P ¼ 0.004), basal anteroseptal (P ¼ 0.04), and basal inferoseptal segments (P ¼ 0.002) compared with HCM patients with a negative genetic test (Table 3, Figure 3 ). There were no significant differences in the other 14 segments. Strain patterns in reverse curve, genotype-positive HCM patients differed significantly from genotype negative patients with sigmoidal curvature in multiple segments (Table 4, Figure 4 ). Specifically, differences were noted within the mid anteroseptal (P ¼ 0.01), mid inferoseptal (P , 0.001), mid inferior (P ¼ 0.02), basal anterior (P ¼ 0.02), basal anteroseptal (P ¼ 0.003), and basal inferoseptal (P ¼ 0.002), averaged mid strain (P ¼ 0.02), averaged septal strain (P ¼ 0.02), and averaged global strain (P ¼ 0.02).
To further investigate these regional longitudinal strain differences, subgroup analysis was performed comparing genotype-negative and genotype-positive patients with the same curvature pattern ( Table 5) . When grouped within the same septal curvature pattern, the previously noted regional strain differences were no longer statistically different within any curvature pattern. Furthermore, no other global differences were identified.
Exclusion of patients with prior myectomy or alcohol septal ablation therapy (n ¼ 43) was performed to evaluate for prior septal reduction therapy as a confounder. With these patients excluded, longitudinal strain assessment in the basal anteroseptum (210 + 6 in genotype positive vs. 28 + 5 in genotype negative, P ¼ 0.048) and basal inferoseptum (213 + 6 in genotype positive vs. 210 + 5 in genotype negative, P ¼ 0.03) remained significantly different. While the mid inferoseptum was no longer statistically different (213 + 6 6 in genotype positive vs. 215 + 6 in genotype negative, P ¼ 0.1), it was trending in the same direction as the primary analysis. As with the primary analysis, upon inclusion of septal morphology, there were no regional differences in LV deformation.
Among the patients with a positive genetic test, strain was not significantly different when comparing patients with the same septal morphology but having a different HCM-susceptibility gene (data not shown Deformation patterns in genotyped HCM reverse curve-HCM, the deformation characteristics were similar between MYBPC3-and MYH7-mediated HCM.
Patients with reverse curve morphology had significantly thicker ventricular septal dimensions than patients with sigmoid morphology (20 + 5 vs 15 + 5 mm, P , 0.0001). For all patients, global longitudinal systolic strain demonstrated a modest positive correlation with maximal septal thickness (r ¼ 0.34, P , 0.0001), with a stronger correlation noted between basal anteroseptal longitudinal strain and maximal septal thickness (r ¼ 0.54, P , 0.0001).
Discussion
Our study found that there are no differences in global longitudinal strain between genotype-positive and genotype-negative HCM patients. While regional differences in longitudinal strain exist in genotyped patients with HCM, these regional differences are secondary to the pattern or degree of hypertrophy as opposed to genotype. These data suggest that LV deformation patterns do not predict a positive genetic test and therefore, echocardiographically guided genetic testing still relies principally on the manifest pattern of hypertrophy.
On the basis that echocardiographically-guided pre-genetic test counselling is of clinical value (as reverse curve septal morphology is one of the strongest predictors of a positive genetic test 11, 12 ), we initially hypothesized that LV deformation patterns, identified via prospective speckle-tracking peak longitudinal strain, would further differentiate genotype negative and genotype-positive patients with overt HCM. In all studied patients, longitudinal strain was obtained prospectively, which allowed for real-time image optimization to ensure quality speckle-tracking in each segment. Longitudinal strain assessment revealed no differences in global deformation between patients with an HCM-causative mutation and those patients whose HCM remains genetically elusive. While regional differences in LV deformation were identified in multiple segments, analysis accounting for septal morphology ( Table 5 ) nullified these differences. Furthermore, strain (both global and segmental) correlated with degree of septal hypertrophy. These data imply that abnormalities in regional deformation are related to the septal geometry, not genetic underpinnings.
HCM remains a heterogeneous condition on many levels: clinical, echocardiographic, hemodynamic, histologic, and genetic. Our study included patients who had undergone ICD implantation and those with prior septal reduction therapy. These variables have the potential to confound the presented strain analysis. All included analyses were performed on patients in a non-paced state, to eliminate alteration of LV deformation with non-native electromechanical coupling. Patients with prior septal reduction therapy were included in the primary analysis. However, exclusion of these patients resulted in similar regional differences between genotype-positive and genotype-negative patients, which continued to be negated when septal contour was considered. As this exclusion did not alter overall study results significantly, prior septal reduction therapy is not felt to be a significant confounder of present analyses.
HCM is a leading cause of sudden cardiac death (SCD) in young individuals and a relatively common inherited cardiac disease, affecting an estimated 1 in 500 people. 29, 30 Considering their substantial phenotypic and genotypic heterogeneity and a strikingly variable natural history, patients with HCM often represent diagnostic and therapeutic dilemmas. Within HCM, the degree and morphology of hypertrophy, extent of fibrosis and myocardial fibre disarray, and the presence or absence of LV outflow tract obstruction differ widely; accordingly the clinical course is substantially variable. Moreover, there is considerable overlap between genetic heterogeneity, morphological features, and the many manifestations of natural Gene (2), n 5 39
Gene (2), n 5 13
Gene (2), n 5 17
Gene (2), n 5 11 P Average strain (%) Deformation patterns in genotyped HCM history. Symptoms range from lifelong asymptomatic hypertrophy to SCD or medically refractory severe exertional dyspnoea and fatigue necessitating septal reduction therapy. Transthoracic echocardiographic evaluation of myocardial strain with speckle tracking analysis provides a sensitive approach to assess global and regional myocardial function and is becoming increasingly used in patients with HCM and other cardiomyopathies. The relationship of regional deformation to the presence or absence of genotypic mutations in overt HCM has yet to be described but is an area of potential interest as an approach towards correlating phenotype and natural history. Regionality of strain pattern abnormalities has been correlated previously with septal morphology, consistent with our findings. 31 However, how this relates to genotype remained unclear. Ganame et al. previously assessed strain in paediatric populations of HCM and Freidrich's ataxia. No differences were identified in echocardiographic variables between patients with isolated concentric HCM and Friedreich's ataxia with resulting HCM, suggesting that the pattern of hypertrophy influences myocardial deformation more than the underlying cause of HCM. 32 Furthermore, within HCM, genotype has not been associated with significant differences in degree of myocyte disarray. 33, 34 Our results support these findings within adult populations of overt HCM. Strain imaging provides insight into dynamic tissue properties in HCM. From the standpoint of tissue characterization, myocardial fibrosis on cardiac MRI has been associated with depressed longitudinal systolic strain 19 and at histopathology the degree of myocyte hypertrophy, disarray, and interstitial fibrosis have been correlated with systolic and early diastolic septal strain rate. 35 However, systolic longitudinal, circumferential, and radial strain measures are decreased even in the absence of fibrosis. 19 This suggests functional influences on strain parameters. Although labile obstruction has potential to affect findings, longitudinal, radial, and circumferential strain and strain rate are significantly reduced in non-obstructive patients. 36 Recent elegant studies have demonstrated prolongation of systolic twist, delayed peak untwist velocity, and limited completion of untwist during early diastole in HCM, 37, 38 providing a mechanistic link between augmentation of systole and global early diastolic dysfunction. In addition to global assessment, strain analysis allows for segmental evaluation, as in this study. Although regional strain assessment in HCM has largely focused on systolic analysis, peak early diastolic strain rate may represent a sensitive index for regional diastolic function. 39 While our findings indicate that strain patterns do not supplement existing predictors of genotype positivity, they do raise several developmental questions. Does the pattern and extent of hypertrophy confer a different strain pattern, or do underlying strain abnormalities result in changes in septal morphology and thickness? We hypothesize that genotype-defined molecular changes influence strain patterns, resulting in different patterns of hypertrophy. The prior findings that there are regional differences between preclinical genotype-positive HCM patients and controls supports this hypothesis. 4 With the knowledge that septal morphology is influenced by genotype, is strain directly or indirectly influenced in this manner? We hypothesize that molecular changes preceding overt hypertrophy may drive strain patterns, in turn driving a predilection for particular septal geometries. However, once overt hypertrophy has manifest, it appears that hypertrophy itself is a driver for LV deformation patterns. Thus, in clinical HCM patients such as those evaluated in this study, it is the pattern of hypertrophy which results in longitudinal strain abnormalities, obscuring any insight into genetic underpinnings. Further study is warranted to explore these issues, as both genotype-positive and genotype-negative patients can still manifest with precisely the same septal morphology. Ongoing research into the genetic basis of HCM, which continues to identify novel underlying genes, may also shed light on this relationship.
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Limitations
This study originates from a single tertiary referral centre and has a potential for referral and selection bias. The studied population had a high incidence of family history of HCM (41%), family history of SCD (24%), ICD implantation (27%), and prior septal reduction therapy (33%). As such, this may not be representative of all patients with HCM. There were limited number of genotype-positive patients with apical and neutral patterns of hypertrophy, which, while expected given the strong association of reverse curvature in genotype positivity, limits subgroup analyses. However, we feel that the study population presents a valid initial assessment of longitudinal strain in a genotyped population. This study solely assessed longitudinal strain, as these data were collected prospectively. Consideration could be given to further analysis of other strain parameters, such as circumferential strain, radial strain, and torsion to evaluate for differences between patients with a positive genetic test and patients with a negative genetic test for HCM.
Conclusion
As new technologies emerge to assess myocardial performance and tissue characterization, it is important to recognize the relationship of these diagnostic findings to other modalities. Our data suggest that among patients with HCM, the marked differences in longitudinal and regional deformation are attributed predominantly to the manifest anatomical/septal morphological subtype of HCM, rather than patients' primary pathogenic substrate.
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